| | | |
| |
Company News:
Xantrex Q4 and 2007 Results and Investor Conference Call
(Download PDF version)
VANCOUVER, B.C., February 14, 2008 – Xantrex Technology Inc. (TSX:XTX) will release its fourth quarter and 2007 results after the Toronto Stock Exchange closes on Tuesday, February 26, 2008. To discuss the results, a conference call has been scheduled for Wednesday, February 27, 2008 at 6:00 am Pacific Time (9:00 am Eastern Time).
The conference call will include presentations by Xantrex’s Chairman Mossadiq Umedaly, Chief Executive Officer John Wallace and Vice President and Chief Financial Officer Jay Biskupski. After the presentations, Xantrex will accept questions from analysts and institutional investors.
The live conference call may be accessed by telephone, by dialing 416-644-3418 or 604-677-8677, and by web, through the Xantrex website at www.xantrex.com/invevents.asp.
Following the call, an audio replay of the conference call will be available at 416-640-1917 (passcode # 21263284#) and the web audio replay will be available from the Xantrex website at www.xantrex.com/invevents.asp.
About Xantrex Xantrex Technology Inc. (www.xantrex.com) is a world leader in the development, manufacturing and marketing of advanced power electronic products and systems for the renewable, programmable, mobile, and portable power markets. The company’s products convert and control raw electrical power from any central, distributed, renewable, or backup power source into high-quality power required by electronic and electrical equipment. Headquartered in Vancouver, British Columbia, the company has facilities in Arlington, Washington; Livermore and San Diego, California; Elkhart, Indiana; Barcelona, Spain; and Reading, England. Xantrex is listed on the Toronto Stock Exchange under the ticker symbol "XTX".
Note that this news release contains forward-looking statements related to Xantrex Technology Inc. Such statements reflect the current views of Xantrex with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in these forward-looking statements.
For further information, please contact: Donna Clark 604-422-2601
donna.clark@xantrex.com
| |
| | | |
|
|
|